While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including new semaglutide ...

A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...

Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...

Scientists are trying to tackle Alzheimer's from all angles, and a new study adds to the growing evidence that semaglutide, a ...

The FBI has issued a warning about counterfeit versions of compounded weight loss drugs, which have been found to contain "unknown drugs, hig ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

While anecdotal evidence suggests those taking the type 2 diabetes drug with a side effect of weight loss may lead to hair ...